Core Insights - The core prediction for 2026 is that "AI applications will be like real estate in 2006" [2][11][37] - The innovative pharmaceutical sector is seen as the beginning of a long bull market, with expectations for significant developments in the coming year [2][17] - Index-based investment in innovative pharmaceuticals is considered to have good investment value under the premise of an efficient market [2][10] Group 1: AI Applications - There has been limited significant profit from AI applications by investors so far, but 2026 is anticipated to be the year of explosive growth in this area [2][12][31] - The A-share and Hong Kong markets are expected to present substantial opportunities in AI applications [2][13][34] - The Hong Kong market has a clear advantage, with many quality strategic emerging AI companies and innovative pharmaceutical firms listed there [2][14] Group 2: Innovative Pharmaceuticals - Innovative pharmaceuticals are characterized as a "life-or-death" business, but they show promising investment potential in an efficient market [4][7][10] - Long-term investments in leading innovative pharmaceutical companies have yielded impressive returns in both the US and Japan [8][28] - The American innovative pharmaceutical ETF has outperformed the S&P 500, highlighting the sector's potential [9][29] Group 3: Market Conditions and Investment Strategies - Regardless of interest rate changes, investment in AI and innovative pharmaceuticals is expected to grow [2][15][35] - For fundamental investors, the valuation adjustments during a rate-cutting cycle may present better buying opportunities [2][21][36] - The current market structure is highly differentiated, with increasing investment demand in AI and innovative pharmaceuticals, which are less affected by interest rate fluctuations [2][15][35]